WATCHLONGEVITY

Sunday, June 21, 2026

Amgen launches late-stage obesity trial in patients who switch from rival drugs
BREAKING
Importance
78
Trust
71
Urgency
95
CLINICAL TRIAL

Amgen launches late-stage obesity trial in patients who switch from rival drugs

Amgen started three big trials for MariTide, its obesity drug. One trial will test MariTide in patients switching away from rival weight-loss drugs made by Eli Lilly and Novo Nordisk.

Analysis

Amgen wants to prove MariTide works for people who quit Ozempic or Zepbound. A win could pull patients away from Lilly and Novo.

  • Amgen started three late-stage trials of its obesity drug MariTide
  • One trial enrolls patients switching from Lilly or Novo weight-loss drugs
$AMGN$LLY$NVO
maritideglp-1 agonistsAmgenEli Lilly
Endpoints News1mo
Read
Importance
62
Trust
71
Urgency
30
SCIENCE

NeuroDex and Stanford Researchers Publish First Evidence of CNS Target Engagement for GLP-1 and PPARγ Agonists Using Blood-Based Neuron-Derived Extracellular Vesicles - BioSpace

NeuroDex and Stanford researchers showed that GLP-1 drugs (weight-loss medicines) reach the brain and affect it. They used a new blood test with tiny particles from nerve cells to measure this effect for the first time.

Analysis

A new blood test can show if GLP-1 drugs reach the brain. This could help prove how weight-loss drugs work and speed up testing of new ones.

  • NeuroDex and Stanford published first evidence of CNS target engagement for GLP-1 drugs
  • Test uses neuron-derived extracellular vesicles drawn from blood
  • Method also covers PPARγ agonists
$NVO$LLY
glp-1 agonistsNeuroDex
BioSpace1mo
Read